Clinical trial
Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited…
NCT00433641 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00433641 |
|---|---|
| Title | Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes |
| Official title | Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | sibutramine |
| Enrollment | 181 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 12, 2007 |
| Last update posted | Mar 14, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: